Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO2015179833) COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UNE RÉSISTANCE AUX ANTICORPS
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

What is claimed:

An isolated nucleic acid sequence encoding an immune receptor (IR), wherein the isolated nucleic acid sequence comprises a human nucleic acid sequence of a Fc receptor (Fc) binding domain, and a nucleic acid sequence of an intracellular domain of a costimulatory molecule.

The isolated nucleic acid sequence of claim 1 , wherein the Fc binding domain is selected from the group consisting of CD64, CD32, CD 16, a fragment thereof, and any combination thereof.

The isolated nucleic acid sequence of claim 1, wherein the intracellular domain comprises at least one signaling domain of the co-stimulatory molecule.

The isolated nucleic acid sequence of claim 1, wherein the intracellular domain comprises at least one signaling domain selected from the group consisting of CD3, CD28, a fragment thereof, and any combination thereof.

The isolated nucleic acid sequence of claim 1 further comprises a nucleic acid sequence of a transmembrane domain.

A population of cells comprising the isolated nucleic acid sequence of claim 1.

A vector comprising an isolated nucleic acid sequence encoding an immune receptor (IR), wherein the isolated nucleic acid sequence comprises a human nucleic acid sequence of a Fc receptor (Fc) binding domain and a nucleic acid sequence of an intracellular domain of a costimulatory molecule.

An isolated immune receptor (IR) comprising a Fc receptor (Fc) binding domain and an intracellular domain of a costimulatory molecule.

The isolated IR of claim 8, wherein the Fc binding domain is selected from the group consisting of CD64, CD32, CD 16, a fragment thereof, and any combination thereof.

10. The isolated IR of claim 8, wherein the co -stimulatory molecule is selected from the group consisting of CD3, CD27, CD28, ICOS, 4-1BB, PD-1, T cell receptor (TCR), co- stimulatory molecules, any derivative or variant of these sequences, any synthetic sequence that has the same functional capability, and any combination thereof.

11. The isolated IR of claim 8 further comprising a transmembrane domain.

12. The isolated IR of claim 8, wherein the IR is capable of binding an antibody.

13. A modified T cell comprising an isolated immune receptor (IR) comprising a Fc receptor (Fc) binding domain and an intracellular domain of a costimulatory molecule.

14. The modified T cell of claim 13 further comprising an antibody bound to the Fc binding domain, wherein the antibody binds a target cell.

15. A pharmaceutical composition comprising the modified T cell of claim 13 and a

pharmaceutically acceptable carrier.

16. Use of the modified T cell of claim 13 in the manufacture of a medicament for the

treatment of an immune response in a subject in need thereof.

17. A method of treating a disease or condition associated with resistance to an antibody- mediated therapy in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising the modified T cell of claim 13.

18. A method of treating a condition in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising the modified T cell of claim 13.

19. A method for stimulating a T cell-mediated immune response to a target cell or tissue in a subject comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising the modified T cell of claim 13.

A method of overcoming resistance to an antibody-mediated therapy in a subject, the method comprising administering to the subject an effective amount of a modified T cell comprising an immune receptor (IR), wherein the immune receptor comprises a Fc receptor (Fc) binding domain and an intracellular domain of a costimulatory molecule, thereby overcoming resistance to the antibody-mediated therapy in the subject.

A method of treating a tumor in a mammal, the method comprising administering to the subject an effective amount of a genetically modified cell comprising an immune receptor (IR), wherein the immune receptor comprises a Fc receptor (Fc) binding domain and an intracellular domain of a costimulatory molecule.

The method of any one of claims 20 or 21, wherein the administration comprises administering an antibody for a target cell prior to administering the effective amount of the modified T cell.

The method of any one of claims 20 or 21, wherein the administration comprises binding the modified T cell to an antibody with specificity for a target cell.